Abstract: ObjectiveTo discuss the safety and short-term efficacy of ticagrelor in patients with acute coronary syndromes in Chinese． MethodsA total of 199 acute coronary syndromes patients were enrolled．96 of them were given ticagrelor and the other 103 were given clopidogrel． We observed the adverse events in 10 days, 30 days and 90 days, and compared ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300 to 600 mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events and bleeding in 90 days． ResultsThere was no significant difference in basic clinical data and related routine examination results between two groups (P >0.05). Patients receiving ticagrelor had lower ratio in cardiovascular death (1% vs. 1.9%), myocardial infarction (0% vs. 1%), stroke (0% vs. 1.9%), stent thrombosis (0% vs. 1%) and recurrent ischemia (2.1% vs. 4.9%) and higher ratio in dyspnea (2.1% vs. 0%), minor bleeding (3.1% vs. 1.0%) and minimal bleeding (5.2% vs. 2.9%) than those receiving clopidogrel with no significant difference(P>0.05). There was no major bleeding in both groups. The ratio of major adverse cardiovascular events was much lower in patients receiving ticagrelor than those receiving clopidogrel (3.1% vs. 10.7%; P =0.037)． The total ratio of minor bleeding and minimal bleeding was higher in those receiving ticagrelor with no significant difference (8.3%, vs. 3.9% with clopidogrel; P =0.188). ConclusionThe safety and short-term efficacy of ticagrelor in patients with acute coronary syndromes in Chinese were in accordance with PLATO．

Key words: ticagrelor, acute coronary syndrome, adverse cardiovascular events, short-term efficacy, safety